Please ensure Javascript is enabled for purposes of website accessibility

Bayer Settles Roundup Lawsuit for Almost $11 Billion

By Howard Smith – Jun 24, 2020 at 4:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The plaintiffs said the weedkiller caused their cancers. Bayer became the defendant after acquiring its manufacturer, Monsanto, for $63 billion in 2018.

Diversified German chemical and pharmaceutical company Bayer (BAYR.Y -1.36%), has agreed to settle litigation over allegations that the weedkiller Roundup causes cancer in people exposed to it. The company, which inherited the product when it purchased chemical maker Monsanto in 2018, said resolution of the lawsuits will cost it between $10.1 billion and $10.9 billion, including addressing potential future litigation. 

Bayer says it will fund the settlement in part by selling its animal health business, and cover the rest through its free cash flow. The company reported free cash flow of approximately $4.7 billion in 2019. It said the resolution "will bring closure to approximately 75% of the current Roundup litigation involving approximately 125,000 filed and unfiled claims overall." This includes about 95% of cases currently set for trial. The settlement provides a framework for resolving the remaining cases. 

worker spraying bushes with weedkiller chemical

Image source: Getty Images.

The lawsuits revolved around the health hazards of the chemical glyphosate, which is a key ingredient in the product. Bayer said its decision to settle was based on a risk assessment versus potential costs and outcomes of continuing litigation, "and associated reputational and business impacts."

However, Bayer still asserted that "the extensive body of science indicates that Roundup does not cause cancer, and therefore, is not responsible for the illnesses alleged in this litigation." 

Scotts Miracle-Gro (SMG -3.10%) has also said it believes in the safety of the Roundup product if used properly. Scotts is the U.S. marketing agent for the well-known weedkiller, but its executives said in a 2018 earnings conference call that it is indemnified against any litigation related to glyphosate, and is not financially liable in any of the lawsuits. 

Howard Smith has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Scotts Miracle-Gro. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bayer Stock Quote
Bayer
BAYR.Y
$11.56 (-1.36%) $0.16
The Scotts Miracle-Gro Company Stock Quote
The Scotts Miracle-Gro Company
SMG
$42.75 (-3.10%) $-1.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.